Category Archives: Marijuana Penny Stocks

marijuana stocksMarijuana Penny Stocks

The Cannabis sector has been one of the hotest secotrs in the stock market. Countries all over the world are starting to jump on the marijuana bandwagon and pass legislation in order to legalize pot. Below you will find a list of Marijuana Penny Stocks. These stocks have the potential to explode if the US decides to legalize marijuana on a federal level.

Abattis Bioceuticals Corp. (ATTBF)

Aero Grow International Inc. (OTCMKTS:AERO)

Blue Line Protection Group (BLPG)

Cannabis Sativa Inc. (CBDS)

CannaGrow Holdings Inc (OTCMKTS:CGRW)

Cara Therapeutics (NASDAQ:CARA)

CGrowth Capital Inc (OTCMKTS:CGRA)

DigiPath, Inc (OTCMKTS:DIGP)

Electronic Cigarette International (ECIG)

Endexx (EDXC)

Full Circle Capital Corp (NASDAQ:FULL)

General Cannabis (OTCQB:CANN)

GreenGro Technologies Inc (OTCMKTS:GRNH)

Grow Condos, Inc. (OTCQB:GRWC )

Growblox Sciences Inc (OTCMKTS:GBLX)

GW Pharmaceuticals is a Hot Stock to Own with Several Bullish products

Hemp Inc (OTCMKTS:HEMP)

Indoor Harvest Corp, (INQD)

INSYS Therapeutics, Inc.

Lexaria Bioscience Corp. (LXRP)

Marijuana Industry is Risky, Traders are looking to Profit from Investments

Headquartered in Henderson, Nevada, mCig Inc. (OTCQB:MCIG)

Medicine Man Technologies (MDCL)

Mettrum Health Corp is on the Verge of Rebound

Plandai Biotechnology Inc (OTCMKTS:PLPL)

Rocky Mountain High Brands, Inc (OTCMKTS:RMHB)

Scotts Miracle-Gro Co. (NYSE:SMG)

Surna Inc (OTCMKTS:SRNA)

Terra Tech Corp (OTCMKTS:TRTC) is Set for Big Profits

The Future of the Marijuana Industry

Tweed Inc. (Tweed), wholly owned subsidiary of Canopy Growth

Corporation (Canopy Growth) (TSX: CGC) (OTC: TWMJF)

Two Rivers Water & Farming (OTCQB:TURV)

United Cannabis Corp. (OTCBB:CNAB)

Vapir Enterprises Inc. ( OTCQB:VAPI)

VPR Brands Continues to Grow

Zynerba Pharmaceuticals has Further Upside

Agree Realty $ADC

Alternaturals Inc. $ANAS

American Green Inc. $ERBB

Arena Pharmaceuticals $ARNA

Cannabics Pharmaceuticals $CNBX

Cannabis Capital $CBCA

Cannabis Science Inc (OTCMKTS:CBIS)
Cannabis-Rx, Inc. (OTCBB CANA)
Easton Pharmaceuticals Inc (OTCMKTS EAPH)
Inergetics Inc (OTCMKTS:NRTI)
Latteno Food Corp. (LATF)
Lexaria Bioscience Corp (OTCMKTS: LXRP)
Medican Enterprises Inc (OTCMKTS: MDCN)
Medicinal Marijuana, Inc. (OTCPK:MJNA)
MENTOR CAPITAL INC COM NPV (OTCMKTS:MNTR)
MMRGlobal, Inc., (MMRF)
Northsight Capital, Inc. (OTCBB NCAP)
Notis Global Inc (OTCMKTS:NGBL)
NOVUS ACQ and DEV (OTCMKTS:NDEV)
Puget Technologies, Inc. (OTC PUGE)
Sipp Industries (SIPC)
Stevia Corp (OTCMKTS:STEV)
Vapor Corp. (OTC:VPCO)
Vapor Group (VPOR)
VAPR’s (VAPR)

Hemp Inc (OTCMKTS:HEMP)

Hemp Inc (OTCMKTS:HEMP)

Perhaps no other name has personified the pot stock boom and bust more so than Hemp Inc (OTCMKTS:HEMP). The company’s share price currently trading around 0.02 a share and its 52 week range is $0.00 – $0.12 per share. Its outstanding shares are around 754,027,180, while authorized shares are at 5,500,000,000.

Hemp’s administration expects more beneficial business open doors in coming period. The purpose for this developing good faith is news of another state joining the gathering of 29 expresses that have legitimated industrial hemp.

Tom Wolf, the Governor of Pennsylvania, marked a bill that would permit the Pennsylvania Agriculture Department and in addition establishments of advanced education develop hemp for exploration use, specifically or through approved temporary workers.

Hemp’s auxiliary unit, IHM, is in the last period of conclusion. David Schmitt, the COO of IHM, said that modern hemp is recovering its reasonable position in the U.S. as demand for this normal fiber keeps on surging because of the economic advantage. Pennsylvania brags a rich history of hemp cultivating since 1700s. Truth be told, it had one district which was even named “Hempfield.” The awareness is developing as more states are prepared to attach to existing American society.

The tragic part is that Hemp was really gaining some ground. A month ago and following quite a while of holding up, Hemp at last created its first naturally benevolent item to-market from the organization’s new decortication plant in Spring Hope, North Carolina.

This was an entirely major ordeal for HEMP and its speculators as the organization has fundamentally wagered the farm on this plant and the condition of North Carolina. Analyst believes that the organization was making a rebound and things were at long last beginning to meet up.

CV Sciences Inc (OTCMKTSCVSI)

CV Sciences Inc (OTCMKTSCVSI)

CV Sciences Is on Uptrend

CV Sciences Inc (OTCMKTS:CVSI) is a stock that has been driving in an uptrend helped along by late energy in the cannabis-related space as we rush into the real impetus one week from now on Tuesday. That is when almost 33% of the US populace will hit the voting stalls to set down judgment on the future legitimateness of pot crosswise over nine distinct states.

Be that as it may, CVSI kept running into close term reality this week when the organization came to advertise with its most recent financials. Long story short, the best possible move here was taken by the organization as far as speculator relations: concentrate on the pipeline and R&D activities on the grounds that the present numbers aren’t much to keep in touch with home about.

CVSI outlines itself as an existence science organization, concentrates on creating and commercializing novel therapeutics using engineered Cannabidiol (CBD).

CVSI works two particular business fragments: a medication improvement division concentrated on creating and commercializing novel therapeutics using engineered CBD; and, a buyer item division in assembling, advertising and offering plant-based CBD items to a scope of market segments, including nutraceutical, magnificence mind, forte sustenances, and vape.

Taking after the CanX Acquisition in December 2015, CV Sciences started its preclinical medication improvement program amid the second quarter of 2016. The Company’s medication advancement endeavors incorporate seeking after manufactured based Cannabidiol tranquilize applicants in zones that can possibly give noteworthy changes in remedial patient medicines with sizable addressable markets.

CVSI was once in the past known as CannaVEST Corp. furthermore, changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. has essential workplaces and offices in Las Vegas, Nevada and San Diego, California.

CVSI is driven by Michael J. Mona, JR. organizer of CV Sciences, Mr. Mona has more than 30 years of senior administration involvement in a scope of enterprises including land/development, mechanical cultivating, synthetic handling and customer items. Mr. Mona is a perceived industry pioneer in hemp cultivating operations and compound extraction and has built up a worldwide store network of hemp-inferred items.

Creative Edge Nutrition Inc- FITX

Creative Edge Nutrition Inc (OTCMKTS:FITX)

Creative Edge Nutrition Is Moving in a Positive Direction

Creative Edge Nutrition Inc (OTCMKTS:FITX) keeps on moving relentlessly higher as of late since switching off $0.0025 lows prior this year. The stock keeps on getting a help from news on its backup Giddy Up Energy Products, Inc., and its arranged dispatch of its two starting caffeinated drink flavors, Peach Mango and Cherry Pear.

Like no other pot stock FITX was the best in catching the creative abilities and wallets of little top financial specialists. At its tallness the stock was practically similar to a clique with shareholders offering shirts that said “FITX-Long” or “I-Billieve” (as in president and CEO of FITX, Bahige “Charge” Chaaban).

Pot stocks (and FITX will move with the segment) might be in for another blast; DEA being advised by California judge to quit meddling with dispensaries, 6,000 peaceful medication guilty parties were just discharged Nov 1, New York opening restorative MJ dispensaries January, Australia lifting restriction on therapeutic MJ. Another huge one is Canada’s new Prime Minister Justin Trudeau who has been promising legitimization quickly in Canada.

FITX is the umbrella holding organization situated in Madison Heights, Michigan. The Company is going up by new CEO James Robinson who have a dream to dispatch an industry driving caffeinated drink line and to quicken income, accomplish benefit and shareholders’ esteem. Under the FITX umbrella, there are 2 essential business auxiliaries:

CEN-BIOTECH as beforehand depicted “This auxiliary is included underway and conveyance of therapeutic pot, and is situated in Lakeshore, Ontario, simply outside Windsor in Canada. FITX is one of the not very many genuine “MMJ” stocks which will really create the maryjane, rather than most other that are included with other subsidiary parts of the weed, for example, CBD extricates, CBD examine, edibles, smoking or developing gadgets, and so on.”

Update: Canada’s Legislation Could Enhance Creative Edge Nutrition Shares

Creative Edge Nutrition Inc (OTCMKTS:FITX) keeps on moving relentlessly higher as of late since turning around off $0.0025 lows prior this year. The stock keeps on getting a support from news on its auxiliary Giddy Up Energy Products, Inc., and its arranged dispatch of its two introductory caffeinated drink flavors, Peach Mango and Cherry Pear.

Like no other pot stock FITX was the best in catching the creative energies and wallets of little top financial specialists. At its stature the stock was practically similar to a religion with shareholders offering shirts that said “FITX-Long” or “I-Billieve” (as in president and CEO of FITX, Bahige “Charge” Chaaban).

CEN-BIOTECH as already portrayed “This auxiliary is included underway and appropriation of medicinal marijuana, and is situated in Lakeshore, Ontario, simply outside Windsor in Canada. FITX is one of the not very many genuine “MMJ” stocks which will really create the pot, rather than most other that are included with other subsidiary parts of the marijuana, for example, CBD extricates, CBD look into, edibles, smoking or developing gadgets, and so on.”

Canada’s legislature is concentrating a government team’s proposals on how it could authorize marijuana, following through on Prime Minister Justin Trudeau’s 2015 decision battle guarantee.

The proposition incorporate a base buy age of 18, elected oversight on creation, commonplace governments accused of retail dispersion and keeping up criminal offenses for unlawful generation and trafficking.

Cannabis-Rx, Inc. (OTCBB CANA)

Cannabis-Rx, Inc. (OTCBB CANA)

Cannabis-Rx, Inc is a Good Stock to Hold

The real story behind Cannabis-Rx, Inc. (OTCBB: CANA) stock is basically the same as it is for almost every other marijuana stock that’s on the OTC Market, regardless of whether they are an SEC reporting company or listed on the Pink Sheets. CANA wants to become the go to company when marijuana growers and vendors are looking to lease space – the marijuana related real estate market.

Within the promotional material, the emphasis after all of the metaphoric realities of what you could have done with your money had you invested it at the right time.

The company plans to lease growing space…provide access to commercial real estate and equipment…and provide access to operating capital for licensed marijuana business operators.

Here’s the reality: marijuana – even with legalization – still comes with a certain “stigma” attached to it. So licensed business operators can have difficulty finding commercial real estate or getting easy access to bank loans.

Cannabis-Rx, Inc stands poised to help those business operators by providing access to the real estate, capital and equipment needed to participate in the rapid growth of this industry.

The company has already raised $16 million – and has plans to raise another $8 million – and they are looking to invest a large amount of wealth into what has quickly become the fastest-growing industry in North America: legal marijuana.

Of course they raised $16 million. They did it by selling CANA stock at a massive discount so that it could be pumped. Shares of CANA stock are currently trading at $3.48 per share, down -0.115 (-11.50%), on volume of 135,985 – not such a great profit story in the legal marijuana industry.

CannaVest (CANV)

CannaVest (CANV),

CannaVest Looks Strong Aimed its Balance Sheet

CannaVest (CANV), exchanging simply off the 52-week lows, is looking increasingly like a magnificent microcap play for those hoping to enter the unstable yet high potential cannabis space. While microcap contributing involves a lifted level of hazard and a specific craving to act in a wander limit it can be unbelievably fulfilling on the off chance that you can distinguish wasteful aspects or unpredictable gathering offering inside an area.

“CannaVest Corp. creates, delivers, markets and offers raw materials and end buyer items containing the hemp plant extricate, Cannabidiol (“CBD”), to the nutraceutical, magnificence mind, pet care, claim to fame drink and practical nourishment areas.

To start with, you ought to comprehend that I’m arguing for a CANV thought working under the suspicion that cannabis will keep on being authorized broadly and that cannabis subsidiary items like those sold by CANV will keep on achieving more extensive social acknowledgment. While this has as of now happened to a more than least level degree, CANV had ~$10.2 million in item deals in entire year 2014, I anticipate that a proceeded with tailwind will be given at cannabis subordinates are coordinated into social standards.

All things considered, CANV surely isn’t a “pot stock” as it has been assembled in and sold off as – you don’t have $10 million or more entire year incomes being a pot stock. CANV has genuine operations, genuine supply concurrences with European providers, genuine appropriation limit, and clearly genuine financial specialists.
CANV as of late shut a $6.5 million financing with an institutional speculator that will be given in a progression of tranches. The financing will be utilized for working capital as CANV hopes to keep on scaling up its operations. This financing alongside liquidity as of now on the CANV monetary record ought to go far into accomplishing organization objectives.

That is the other thing about CANV that is profoundly surprising for a microcap. CANV’s monetary record as of Q1/15 reporting looks strong. The organization had, preceding the financing, $2.23 million in real money, $1.2 million in AR, $2.3 million in prepaid stock, and $10.7 million in stock. Of its aggregate ~$23.4 million in resources just generally $4.2 million was in Intangibles and Goodwill – such a light weighting is an irregularity in the microcap space. CANV likewise just as Accounts Payable of ~$500,000 and no obligation. Once more, that is an extraordinary place to begin.

Cannabis Capital (OTCPKCBCA)

Cannabis Capital (OTCPKCBCA)

Cannabis Capital: A diversified Company Is Set To Grow

Cannabis Capital (OTCPK:CBCA), is looking to enter into the marijuana space through a diversified approach into “actively pursuing investment opportunities in the rapidly growing global Medical Cannabis Industry. CBCA invests in companies positioned to make a significant impact within the global medical and legal marijuana markets.”

According to CBCA, these early stage investments “provide emerging companies with access to larger capital sums to help elevate their status from start-ups to a mature and durable brand leader.” Management finds that recent legislative changes around the world are “creating compelling investment opportunities in which Cannabis Capital is positioned to be an identifier of and an early stage investor in promising companies in the industry.”

Earlier this year in April, Cannabis Capital announced its first strategic acquisition after signing a definitive agreement to acquire WebCongress Inc., which included the retaining of the company’s current executive management team.

According to the company, the package deal is valued at over $25 Million, based on CBCA’s current share price, and consists of a combination of cash, shares, and management fees. Regarding the acquisition, Chad S. Johnson, Esq., Director, President & CEO of Cannabis Capital Corp. stated, “WebCongress possesses both a successful, high-growth business model and a strong executive management team that align well with our combined growth plans.

We acquired WebCongress on mutually beneficial terms and at the right time, being in our early stage of growth and development. We believe this acquisition provides CBCA with a profitable business combination that will enhance and support each company’s core mission, expanding international operations and harmonizing the current services and offerings of WebCongress with CBCA’s development. WebCongress’s accelerated growth will generate ongoing novel opportunities and platforms for the legal cannabis industry on a global basis. This is a key step in the direction of increasing long-term CBCA shareholder value, and we are more than excited to make this announcement.”

Cannabics Pharmaceuticals Inc (CNBX)

Cannabics Pharmaceuticals Inc (CNBX)

It’s time to Buy Cannabics Pharmaceuticals

Cannabics Pharmaceuticals Inc (CNBX) is a biotechnology pharmaceutical organization that is centered around advancement and authorizing of cannabinoid-based medicines and treatments. In that capacity, it creates and showcases different treatments and biotechnological devices went for giving help from infirmities that react to dynamic fixings sourced from the cannabis plant.

CNBX creates and showcases different treatments and biotechnological instruments went for giving help from infirmities that react to dynamic fixings sourced from the cannabis plant. These devices incorporate conveyance frameworks for cannabinoids, customized pharmaceutical treatments and strategies in light of cannabis started mixes, and bioinformatics apparatuses.

Its lead item is CANNABICS SR, which is an innovation for a long acting oil container that gives organization of cannabis. This is created exclusively from nourishment review materials and conveys impacts for more than 10 to 12 hours and the conveyance technique empowers an once every day dosing regimen of medicinal cannabis to patients.

The late decisions in the US additionally included voting on the legitimization of cannabis for medicinal or recreational use in specific states. The yes vote in states, for example, Florida will open a bigger market for this organization, which would mean bigger incomes down the line. Cannabics Pharmaceuticals Inc, be that as it may, hasn’t produced any incomes yet since it has been centered around generally investigate.

Just as of late, CNBX reported an examination achievement in finding a more powerful plan proportion of cannabis parts THC and CBD in fighting growth cells. Specifically, the organization shared that that outcomes from the most recent malignancy HTS look into obviously presume that, contingent on the THC/CBD proportion, particular Cannabis concentrates are straightforwardly contributive to diminishing U87MG glioblastoma cell reasonability.

This will empower the organization to make weed solutions gloating more prominent adequacy, potentially getting a charge out of a steady share of the therapeutic weed showcase. Beside that, the organization could likewise create additional incomes by adapting its disclosure to outsider designers of maryjane solutions.

Is AERO stock a scam? Aero Grow International Inc. (OTCMKTS:AERO)

Aero Grow International Inc. (OTCMKTS:AERO)

Aero Grow International Inc. (OTCMKTS:AERO) is the creator, manufacturer and marketer of the Miracle-Gro AeroGarden line of indoor gardens for consumer markets worldwide. Headquartered in Boulder, Colorado, AeroGrow International is the leader in the rapidly growing indoor gardening market. They are one of the more popular  marijuana stocks.

Updated Version:

 

PROS:

AERO is a thinly traded stock which has the chance at big swings. IT saw several 50% swings in 2018. Will this trend continue in 2019? Over the last year, it seems to have developed some support around $2.20 a share.  As long as that support holds it may make a great swing trade play.

Cons:

Volume has been very low this year compared to time in 2017. Every time it has gone up it seems to come right back down to where it started. It has shown very little growth in the Price per share over the last two years. AERO is still a penny stock and like all penny stocks there are risk involved.

Archived from 2016 post

The company’s stock currently trades around $3.10 per share with an average volume of 17,617 shares. The company’s outstanding shares are standing around 8,574,372, while authorized shares at 750,000,000.

Aero Grow International recently issued its earnings results. It posted earnings per share (EPS) of $0.20 for the quarter, which represents growth of 40% from the same period of last year. It earned $2.16 million in the latest quarter, relative to the consensus estimate of $1.57 million.

Its CEo said “”Net sales for the Company were up 37%, with strong gains in both our retail and direct response businesses — up 56% and 19% respectively. Our retail business experienced good growth with both existing partners such as Amazon and Costco as well as good traction at new partners such as Sur La Table, ACE Hardware and several others. While small, we also made good progress in our European distribution efforts. All of this led to cutting our quarterly EBITDA loss nearly in half from last year — which represents a very solid start for our fiscal year.

The company’s market capitalization stands around $26.24 million. Aero’s 50 day moving average is standing around $2.68 per share, while its 200 day moving average stands around $2.16.

It has extensive business structure and diversified product line. It offers multiple lines of indoor gardens, nutrient formula, grow lights, over 40 seed pod kits, and various gardening, cooking and decor accessories, in Canada and the United States, along with selected countries in Europe, Australia and Asia.

ATTBF is it a scam? Our opinion on Abattis Bioceuticals Corp.

attbf

Abattis Bioceuticals Corp. (ATTBF)

Abattis Bioceuticals Corp. (ATTBF) specializes biotechnology it is a company that is fully involved in the botanical drug development industry. It develops and licenses medicines, natural health products, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets.

The Pros

I like that Abattis is an innovation consolidator. There is a genuine business opportunity by that the company can acquire other companies to expand its presence. One of the greatest challenges for the marijuana business is that specialists are the small producers. Therefore, expanding business through acquisitions is a good strategy. ATTBF has become a popular marijuana stocks and has been receiving a lot of attention.

Abattis Bioceuticals is in position to wind up a pioneer in the developing, testing, and circulation of therapeutic and grown-up use cannabis in North America.

Abattis completed a US$25 million equity line agreement with Dutchess Opportunity Fund. It has agreed to file a registration statement with the U.S. Securities & Exchange Commission covering the Abattis shares that may be issued to Dutchess under this financing.

Overall, it appears that Abattis has a strong liquidity position and the company is in a position to support its expansion strategies. Enhancing liquidity situation through equity offerings is a good strategy for any company in its early stages.

The Cons

ATTBF started 2018 looking like it was about to take off. It reached a high of almost .75 a share.  Unfortunately, since then it has been on a downtrend.  It is down almost 90% from its high. One of the risk of investing in penny stocks is the company are still unproven.

We wanted to dig a little deeper and see if we could figure out why it is having a sell-off.

The first red flag we have is that stockoftheweek.net was compensated 175K for a weekly promotion of ATTBF. This has been going on for a while now.  Looking through ATTBF’s Filings we can see that they took out a lot of toxic debt and notes. These notes converted into common shares at an extreme discount. This is very concerning.  IS ATTBF more interested in creating a profitable company that shareholders can make money with or is it more interested in taking out loans pocketing the money and having the shareholders suffer because of it?

 

United Cannabis Corp. (OTCBB:CNAB)

United Cannabis Corp. (OTCBB:CNAB)

United Cannabis Corp. (OTCBB:CNAB) is an intriguing story in the penny stocks that presently stand at its lows and demonstrated bolster levels. The company’s stock is trading around $0.16 a share with an average volume of 127,595 shares. Its outstanding shares are standing around 45,816,377, while authorized share are at 100,000,000.

CNAB stood out enough to be noticed in 2014 when it kept running from pennies to well over $10 per share amid the pot stock blast that cleared up the bb’s.

The company was established to give initiative to the restorative cannabis industry by offering patient driven arrangements aim on enhancing biomedical and pharmaceutical interests using cannabis-based exploration, items and administrations.

Joined Cannabis Corp appeared in May 2014 after they changed their name from MySkin Inc to mirror the Company’s entrance into the pot business. The shell was initially shaped as a California Corp on November 15, 2007. The Company changed their condition of joining to Colorado when they changed their name to United Cannabis Corp.

Recently, the 250-member Pinoleville Pomo Nation said that they entered into an agreement with United Cannabis to grow marijuana plants on their 99-acre rancheria just north of Ukiah.

The stars adjusted for CNAB when the U.S. Equity Department as of late said that Indian tribes can develop and offer marijuana on their territories the length of they take after the same government conditions laid out for states that have authorized pot.

This opened up the entryway for Indian Reservations to mount huge scale develop operations and United Cannabis Corp alongside FoxBarry Farms has risen as the accepted expert and business accomplice in this new rising multi-billion dollar industry.

CNAB center is to create and license cannabinoid items for an assortment of therapeutics applications and also permit their exclusive programming to doctors looking for cannabinoid-­‐based items.

Terra Tech Corp (OTCMKTS:TRTC) is Set for Big Profits

Terra Tech Corp (OTCMKTS:TRTC) is Set for Big Profits

Maybe the greatest shade on shares of Terra Tech Corp (OTCMKTS:TRTC) has been a reverse split. After second quarter income were accounted for, it a reverse split that was at the forefront of shareholder’s thoughts. The shorts detected the shortcoming and added to Terra Tech plunging underneath $.30 a share.

Be that as it may, now shares are reviving again as a reverse split is solidly off the table. This is awesome news for Terra Tech shareholders and imprints the begin of another bull keep running on the back of Green Rush 2.0 that is going to warm up.

In the second quarter, its generated strong financial performance as TRTC saw development in all cases. Its revenue was standing around $9.7 million, contrasted with $5.0 million in the same time frame in 2015. This is an expansion of 93% from the quarter finished June 30, 2015.

The expansion in second quarter revenue was essentially inferable from sales from the procurement of the Blüm dispensary in Oakland, California, which shut on April 1, 2016, and deals from the Western, Las Vegas Blum dispensary which opened amid the quarter. Second quarter incomes likewise profit by higher Edible Garden offers of its produce, herbs and botanical items.

The company ‘gross margin remains very strong. Its Gross margin for the second quarter of 2016 added up to roughly 17%, contrasted with a gross margin of around 5% for the second quarter of 2015. The enhanced edges were inferable from better margins at Edible Garden, as the business keeps on scaling and higher gross benefit from the cannabis fragments of Blum and IVXX.

Right now, its share is exchanging in the range of 0.37 a share with a market capitalization of $124 million. Its outstanding shares are standing around 349,911,822, while authorized share at 350,000,000

Scotts Miracle-Gro Co. (NYSE:SMG)

Scotts Miracle-Gro Co. (NYSE:SMG)

Scotts Miracle-Gro Co. (NYSE:SMG) is a marketer of branded consumer lawn and garden products. Its products are marketed under the brand names in the industry, including, in North America, Scotts and Turf Builder lawn and grass seed products, including the Miracle-Gro, Scotts, Liquafeed and Osmocote1.

Stock price of consumer lawn and garden products leader, The Scotts Miracle-Gro Company jumped 11.5% a month ago, after the organization reported its monetary third quarter results. Truth be told, the greater part of the stock’s month to month picks up originated from that solitary declaration toward the start of August, which held consistently. The stock is currently up 27% year to date.

Contrasted with the same time frame in 2015, revenue in the latest quarter really dropped 10.5%, to $994 million. The vast majority of the decrease originated from poor climate and the way that the organization moved its monetary timetable, which brought about six less days amid the current year’s second quarter. Gross margin for the quarter developed to 36% and GAAP (sound accounting guidelines) operating income developed to $127 million, contrasted with 34.7% and $115 million, in the year-prior period.

In spite of headwinds from climate and rebuilding, Scotts Miracle-Gro has increased sales by 3% in the initial nine months of its current financial year contrasted with the same time frame a year ago. Gross margin also enhanced, while operating income has grown an astounding 52%. More essential for speculators, administration is ordering a few cost-slicing measures to help operational proficiency, and raised the profit 6%. Scotts additionally procured a stake in two organizations to goad long haul development.

The company’s share are currently trading around $79 a share with an average daily volume of 28,984 shares. Its outstanding shares are standing around 61,411,683, while the company has market capitalization of 4.8 billion.

Marijuana Penny stocks

The marijuana industry has been on a crazy ride over the past few years. These stocks have gained some of the amazing gains you could anticipate with any sector. The reason is the acceptability of cannabis for recreational and medical usage. The industry analysts are predicting a higher growth trend for the cannabis associated stocks without a big risk., However, being a smart investor, it is important to be careful while making investments in this segment. You can lock in some good names and start your personal research to invest your money.

Marijuana is still illegal in many US states and the ones permitting it for medical usage can’t make the weed public to the recreational sector. The selling of marijuana involves paperwork and permission and no one can afford to violate federal law which prohibits the unknown sale of weed. Marijuana companies are forced to deal with payment issues and require authentication to carry forward the process.

Hyped Marijuana Stocks

Marijuana stocks are very hyped and these stocks are based on their state of cash flow at present. This is similar to the tech boom in the early 2000s. In those cases, also, some companies became giants of the industry and the others left the market when the market got into a lot of speculation. Marijuana is expected to have a huge scope in the coming times but it is not sure how the stocks will turn out in the future. Some of the largest penny stocks like GW Pharmaceuticals have their associated drug named Epidiolex which can reduce the frequency of seizures in children. However, the scope of this drug is still not anticipated greatly in the coming future. This is a similar problem faced by many penny stock marijuana companies.

Marijuana Stocks: Mostly Penny Stocks

Most of the marijuana stocks are penny stocks at the moment. It is not a negative thing at all. You just need to understand what you’re dealing with. They might be new companies aiming to get the trust of the investors. There are some stocks which need to be invested and some just need to be day-traded. If you understand the difference between these things, it will be easier for you to make the appropriate investment. There are many debates with respect to marijuana stocks. Some people are a fan of the medical marijuana industry and others are waiting for any positive signal from the research and development team to proceed with the investment in this sector. There is a lot of momentum based on the legalization at the moment. So, if you’re a cannabis stock investor at present, there is nothing to panic. It is important to stay alert and make sure that your trade plan is in the right place.

Like every investment, marijuana stocks diligence and research for getting the best out of a bundle of hundreds of stocks. Penny stock investments are very susceptible to risks and losses and hence, require the personalized approach of the investor to follow their experience and knowledge in selecting the most valuable stocks.  

Marijuana penny stocks 2020

The end of last year was a big high for marijuana stocks with the numbers got gains with the enhanced percentage points. This was due to the legalization of marijuana in several important parts of the US and recreational pot in Canada. There is a lot with the industrial progress of these stocks and marijuana stocks are expected to grow at a wild rate with the growth of this segment all over the Americas.

Marijuana news is still on the major driving pattern of the gains and in the penny stock market, there will be both positive and negative turnarounds for these stocks. The investors need to make the right decision for purchasing the stocks and there are some important factors to consider for checking out the growth of the marijuana industry. The legal bounds are becoming open for the marijuana industry and it is giving a fair chance to some of the new companies growing into this sector. There are long-term gainers and the short-term progressive companies which could be considered for an appropriate move.

Some of the major marijuana stocks like Cronos Group Inc. (NASDAQ: CRON), Hexo Corp (TSE: HEXO) and Canopy Growth Corp (NYSE: CGC) have attained a supreme position in the penny stock market. There have been many gains attained near the year ending of 2018 as the major stock exchanges even played a role in getting the stocks to the high level. Apart from the established companies, there are many companies with the low-priced stocks which have come up with the new concepts for the direct or indirect linkage with the marijuana industry.

All the stocks on the major stock exchanges are not fair and similarly, the stocks on the OTCBB or pink sheets are not necessarily fake. It depends on the investment approach to check out the stocks on different sources. There are different aspects linked to the stock market and diving in the right direction would lead you towards the ultimate success. Pot stocks have made successful ventures for many people all over the world. There are many lists of successful stocks available on the web and the names could be taken for making the research. Ultimately, your own wit will matter in the long run. The business models of companies could be viewed and the plans for forward-looking statements could be checked at various platforms. The marijuana companies move with the activities in its segment. There will be companies having a strong base but are new in the market. Those could be considered for a long-term projection.

Global spending on legal cannabis has hit a value of $57 billion on the global level. There is an increasing demand in the recreational and medical cannabis mainly with the US and Canadian legalization. There are major companies having plans to deal with cannabis stocks in the upcoming times. There are several software applications applying algorithms to check out the financial developments of the companies in the research and ancillary business.

Cannabis Science Inc (OTCMKTSCBIS)

Cannabis Science Inc (OTCMKTSCBIS)

Cannabis Science Could Make a Bid rebound

Cannabis Science Inc (OTCMKTS:CBIS) has been running up the outlines as a standout amongst the most drastically fruitful OTC entertainers available amid the second 50% of 2016. This activity is in direct expectation of the potential for an extended legitimate impression for weed related business in the US that could originate from voting in a few days, on November 8, when about 33% of the US populace partakes in nine state voting choices on the lawful status of cannabis.

CBIS is a penny stock organization that has been taking an interest in the development fervor through dynamic moves striking associations in land bargains for creation and advancement to permit the organization to scale up its volume to meet the bigger market. The diagram indicates 200% attached on to share valuing for the stock in the previous month. Advertise members might need to focus on this stock. CBIS stock has a past covered with sudden tears. Besides, the stock has enlisted expanded normal exchange volume as of late, with the previous month seeing barely short of 310% as time goes all things considered.

CBIS outlines itself as an organization that creates, delivers, and markets phyto cannabinoid-based pharmaceutical items basically in the United States. The organization is included in creating medications for a mental imbalance, circulatory strain, malignancy and growth symptoms, and in addition for different ailments containing for general wellbeing upkeep. It likewise creates CS-TATI-1 for recently determined and treatment-experienced patients to have medicate safe HIV strains, and those narrow minded of accessible treatments; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a restrictive cannabis-based treatment for neurological conditions.

Likewise, the organization offers an online video-based medicinal cannabis stock with instruction framework, including courses, for example, therapeutic cannabis law, restorative pot, cooking, cultivation, and bud tending; and produces and disperses claim to fame steed and pet preparing and topical applications. It has a permit concurrence with Apothecary Genetics Investments LLC to create different brand details for California therapeutic cannabis advertise.

The organization likewise has joint effort with IGXBio, Inc. to create GenePro, a DNA-based immunotherapeutic medication. Cannabis Science, Inc. is situated in Colorado Springs, Colorado. Cannabis Science Inc is a backup of Weedmaps Media, Inc.

mCig Inc. (OTCQB:MCIG)

Headquartered in Henderson, Nevada, mCig Inc. (OTCQB:MCIG)

Headquartered in Henderson, Nevada, mCig Inc. (OTCQB:MCIG) continues to enhance its organization through servicing the lawful cannabis, hemp and CBD markets through its way of lifestyle brands.

MCIG has transitioned from a vaporizer maker to industry driving substantial scale, full service cannabis development organization with its Scalable Solutions division at present working in the quickly growing Nevada market.

MCIG was in the top 5 of all marijuana stocks five years ago. Since then its popularity has weakened.

The company’s share price currently trades around $0.029 per share with average daily volume of 225,070 shares. Its outstanding shares are standing around 326,755,392, while authorized shares are at 560,000,000.

It recently announced very strong results for fiscal year 2016. The company generated a revenue growth of almost 238% to $1,723,241, compared with the revenue of $509,957 in the same period of last year.

Its gross profit margin also enlarged 169% to $290,773 in fiscal 2016, compared with the gross margin of $108,051 in fiscal 2015

Mike Hawkins, Interim Chief Financial Officer, stated, “We are extremely pleased with the direction and performance of MCIG. We will be hosting our second quarterly shareholders update call on September 20, to discuss its operations and first quarter results of the new fiscal year.

Fiscal 2016 was been much better for shareholders of mCig Inc (OTCMKTS:MCIG) than 2015. There are a number of factors driving this optimism. Most importantly, investors look to have finally gotten over the hangover from the pot stock crash of 2014 and are looking to take advantage of the coming Green Rush 2.0, which looks to be starting this year.

Fiscal 2016 remained a strong years for shareholders of mCig compared with 2015. There are various components driving this positive thinking. Above all, speculators hope to have at last gotten over the after effect from the pot stock accident of 2014 and are hoping to exploit the coming Green Rush 2.0, which appears to begin this year.

Now in 2019 MCIG is struggling and showing why a lot of investors stay away from penny stocks. If the toxic debt notes can stop there may be a chance this stock can recover.

Growblox Sciences Inc (OTCMKTS:GBLX)

Growblox Sciences Inc (OTCMKTS:GBLX)

Growblox Sciences Inc (OTCMKTS:GBLX) is a biotechnology research and development company focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies that target a variety of medical conditions. GBLX has been one of the top marijuana stocks for the last 6-7 years.

Growblox Sciences keeps on moving relentlessly higher as of late on quickening volume and recharged Interest from Investors since climbing off its $0.25 base. GBLX began exchanging as Growblox Sciences Inc in April of a year ago after the name change from Signature Exploration and Production Corp.

GB Sciences’ spearheading independent developing unit detaches and secures the plants growing inside while producing perfect developing situations to guarantee great, immaculateness, and consistency.

The company’s main product line include: TissueBLOX, GrowBLOX, CureBLOX and GB Sciences ApotheCAREians.

TissueBLOX – The tissue culture hatchery is customized to manage lighting, temperature, and dampness to encourage cell augmentation and the arrangement of fetuses and shoots from the sterile explants.

GrowBLOX™ – GB Sciences’ spearheading independent developing unit that secludes and ensures the plants becoming inside while creating perfect developing situations

CureBLOX™ – The CureBLOX™ module empowers us to dispense with the danger of mold development and guarantee that the concoction profile of our items is steady from harvest to reap.
GB Sciences ApotheCAREians – Highly prepared and affirmed ApotheCAREians work with patients to decide their restorative needs, distinguish remedial items, introduce GB Sciences’ application on their hand-held gadgets, and exhibit how to place orders.

Its stock price currently trades around $0.30 per share with an average volume of 97,575 share. Its market capitalization stands around $19 million, while the company has negative earnings per share of $0.14 in the latest earnings release. Its outstanding shares are around 57,448,614, while authorized shares are at 250,000,000. This penny stock company has taken several key initiatives to expand its revenue base and market share. It recently opened first marijuana dispensary in the month of July.

INSYS Therapeutics, Inc. INSY Stock

INSYS Therapeutics, Inc.

INSYS Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products.

This has been one of the worst performing marijuana stocks over the last few years.

Its stock price was around $13.58 in 2016, with a business sector capitalization of $1.1bn. The firm exchanges on the NASDAQ stock trade and is headquartered in Phoenix, Arizona. Its outstanding shares are standing around 69,915,560, while authorized shares at 100,000,000.

Insys Therapeutics creates the larger part of its incomes from one item – Subsys. Subsys is a sublingual shower that gives fast onset torment alleviation to patients experiencing breakthrough cancer pain (BTCP). Subsys has produced contention since its discharge, incompletely in light of the fact that the medication is blamed for being considerably more powerful and addictive than even morphine, and somewhat as a result of the association’s forceful deals rehearses, with medication wellbeing specialists vexed by the extensive variety of medicinal experts endorsing it regardless of the FDA cautioning that it ought to just be recommended by oncologists and torment pros. Keep in mind penny stocks can lack proper funding and take on toxic debt and that is what has been hurting Insy.

In spite of income development of more than half in 2015, incomes seem to have hindered, declining by 12% year over year in the primary quarter, spooking financial specialists.

Further muddling the viewpoint, the firm is confronting various claims and examinations, including examinations from the Department of Health and Human Services, and Attorney Generals in Massachusetts, New Hampshire, Arizona, Illinois, and New Jersey, with respect to the commercialization, showcasing, advancement, and offers of Subsys.

Moreover, the firm has gotten data demands and subpoenas from the USAO of Michigan, Rhode Island, Florida, Connecticut, Kansas, New Hampshire, New York, and Alabama in regards to particular doctors the firm has collaborated with.

General Cannabis (OTCQB:CANN)

General Cannabis (OTCQB:CANN)

General Cannabis (OTCQB:CANN) is the all-in-one resource for the highest quality service providers available to the regulated Cannabis Industry. The company lease grows and related facilities (commercial real estate and equipment) to licensed business operators for their production needs. This has been one of the most popular marijuana stocks over the last five years.

The company has a market cap of over $30 million. The company has recently reported strong results for second quarter of 2016. The company reported sales increased 64% to $701,942 for the three months ended June 30, 2016, compared with revenue of the $427,202 in the same period in 2015.

Its total revenues in the first half of 2016 increased 188% to around $1,394,054, relative with $484,059 in the same quarter of last year.

The company has also been aggressively converting strong revenue growth into higher earnings. General Cannabis reported a loss of $0.09 per share, which represents significant improvement of $0.22 per diluted share compared with the loss of $0.31 per diluted share in the second quarter of 2015.

In the first half of 2016, General Cannabis’ generated a loss of $0.17 per share, compared with the loss of $0.38 in the same period last year. The company improved its earnings potential by $0.21 per share.

Its CEO said, “We are encouraged by the distinct improvement in our revenues in the second quarter. During 2016, we have been focusing on developing our acquired businesses, as well as working on new initiatives. Our service revenues continue to grow significantly, driven by strong growth in our Next Big Crop division and Chiefton,” said Robert Frichtel, CEO of General Cannabis.

There are a number of aspects that are working in the favor of the company, including a sales lift in our apparel business and strong consulting revenue. Its stock currently trades around $0.78 per share with a market capitalization of 11.23 billion. Its outstanding shares are around 14,965,421, while authorized shares are around 100,000,000. It has a pretty high market cap compared to other penny stocks so that is something to be careful of.

GW Pharmaceuticals GWPH is a Hot Stock to Own with Several Bullish products

GW Pharmaceuticals is a Hot Stock to Own with Several Bullish products

GW Pharmaceuticals Plc engages in the business of discovering, developing and commercializing novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. The company has market capitalization of $1.81B with an average of 208,179.

Even though we have GWPH on our marijuana penny stocks page it isn’t a penny stock.

Its outstanding shares are standing around 21,765,014 while authorized share holders equity of 245 million. This is the marijuana stock with one of the biggest market caps.

Its average share volume is around 208,179 shares with a one year target price of $149 a share.

GW Pharmaceuticals has been a difficult stock to own over the past couple of years. The company ran up to highs of $125 a share on the back of the biotech bullrun, but essentially collapsed (again, on the back of action in the wider biotech market) to March 2016 lows of a little over $38 a share.

On the release of data from one of its three trials, however, an end-March rally saw it gain more than 100%, and it now trades for just over $81 a share.

The company just reported its latest earnings, and has sold off a bit as a result. We see this selloff as an opportunity to get in on a pullback, ahead of what is going to be a catalyst filled 24 months.

The company has cash on hand of $254 million, so liquidity strength shouldn’t be too much of a problem near term.

With such little markets to go at, incomes are not going to be tremendous from either sign, but rather they ought to effectively surpass the organizations present deals and would put the organization on the way to income generation.

That is not so much what’s critical, in any case. The huge thing about grabbing endorsements in these signs is the potential for a development on the affirmed focuses into the more extensive epilepsy space.

There are more than 10 million children in the US that experience the ill effects of epilepsy and that – if the FDA endorses Epidiolex – could rapidly turn into an objective business sector for GW in light of a supplemental NDA.